Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
INNV

INNV - Innovus Pharmaceuticals, Inc. Stock Price, Fair Value and News

$5.49-0.27 (-4.69%)
Market Closed

53/100

INNV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

53/100

INNV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$5.95

Target 3M

$5.86

Target 6M

$5.89

INNV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INNV Price Action

Last 7 days

-7.7%

Last 30 days

2.0%

Last 90 days

19.1%

Trailing 12 Months

45.6%

INNV RSI Chart

INNV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INNV Valuation

Market Cap

744.9M

Price/Earnings (Trailing)

-42.9

Price/Sales (Trailing)

0.84

Price/Free Cashflow

20.6

INNV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$5.95

Target 3M

$5.86

Target 6M

$5.89

INNV Fundamentals

INNV Revenue

Revenue (TTM)

884.7M

Rev. Growth (Yr)

15.09%

Rev. Growth (Qtr)

6.63%

INNV Earnings

Earnings (TTM)

-17.4M

Earnings Growth (Yr)

262.69%

Earnings Growth (Qtr)

1.1K%

INNV Profitability

Return on Equity

-7.09%

Return on Assets

-3.4%

Free Cashflow Yield

4.86%

INNV Investor Care

Shares Dilution (1Y)

0.17%

Diluted EPS (TTM)

-0.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025831.7M853.7M884.7M0
2024741.3M763.9M786.5M806.6M
2023684.1M688.1M699.4M720.8M
2022697.4M698.6M696.8M688.9M
2021620.1M637.8M658.3M676.3M
20200567.2M584.8M602.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Innovus Pharmaceuticals, Inc.

INNV
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.
0
 CEO
 WEBSITEinnovage.com
 SECTORHealthcare
 INDUSTRYMedical Care Facilities

Innovus Pharmaceuticals, Inc. Frequently Asked Questions

INNV is the stock ticker symbol of Innovus Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Innovus Pharmaceuticals, Inc. is 744.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check INNV's fair value in chart for subscribers.

The fair value guage provides a quick view whether INNV is over valued or under valued. Whether Innovus Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Innovus Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INNV.

As of Wed Jan 28 2026, INNV's PE ratio (Price to Earnings) is -42.9 and Price to Sales (PS) ratio is 0.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INNV PE ratio will change depending on the future growth rate expectations of investors.